PP_1170x120_10-25-21

Mylan president Rajiv Malik

Mylan and Biocon Biologics announce launch of Semglee for diabetes care

Mylan and Biocon Biologics announce launch of Semglee for diabetes care

 PITTSBURGH—  Mylan N.V.  and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced on Monday the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not